Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: An incomplete antitumor effect

Nursing

Volumn 25, Issue 2, 1995, Pages

  Greco, Eliana ^a   Fogar, Paola ^a   Basso, Daniela ^a   Stefani, Anna Lisa ^a   Navaglia, Filippo ^a   Zambon, Carlo Federico ^a   Mazza, Saverio ^a   Gallo, Nicoletta ^a   Piva, Maria Grazia ^a   Scarpa, Aldo ^b   Pedrazzoli, Sergio ^a   Plebani, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Ganciclovir; HSV; Pancreatic cancer; Suicide gene therapy; Thymidine kinase

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; THYMIDINE KINASE;

ANIMAL; ARTICLE; BYSTANDER EFFECT; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENE TRANSFER; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS; HUMAN; LIVER TUMOR; METABOLISM; METASTASIS; METHODOLOGY; MOUSE; MOUSE MUTANT; MUTATION; PANCREAS TUMOR; PATHOLOGY; RETROVIRUS;

ANIMALS; ANTIVIRAL AGENTS; BYSTANDER EFFECT; CELL DIVISION; FEMALE; GANCICLOVIR; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MICE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RETROVIRIDAE; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036676939     PISSN: 03604039     EISSN: 15388689     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. Cancer J Clin 2000; 50:7-33.
2. Sperti C, Pasquali C, Piccoli A, et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21:195-200.
3. Miller AD. Human gene therapy comes of age. Nature 1992; 357:455-60.
4. Zhang J, Russell SJ. Vectors for cancer gene therapy. Cancer Metastasis Rev 1996; 15:385-401.
5. Rigg AS, Scarpa A, Pandha HS, et al. Gene therapy for pancreatic cancer. Ital J Gastroenterol Hepatol 1998; 30:462-6.
6. Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 2000; 59:1071-89.
7. Danthinne X, Imperiale MJ. Production of first generation adenovirus vectors: a review. Gene Ther 2000; 7:1707-14.
8. Moolten FL. Drug sensitivity (“suicide”) genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1:279-87.
9. Black ME, Newcomb TG, Wilson H-MP, et al. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci U S A 1996; 93:3525-9.
10. Yang L, Hwang R, Pandit L, et al. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996; 224:405-17.
11. Kimura M, Tagawa M, Takenaga K, et al. Drug resistance to ganciclovir observed in suicide gene therapy is due to the loss of integrated herpes simplex virus-thymidine kinase gene. Int J Oncol 1997; 10:775-8.
12. Cao G, Kuriyama S, Gao J, et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther 1999; 6:83-90.
13. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracile phosphoribosyltransferase fusion gene. Cancer Res 2000; 60:3813-22.
14. Faulds D, Rennie CH. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infection. Drugs 1990; 39:567-638.
15. Aoki K, Yoshida T, Matsumoto N, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8:1105-3.
16. Grignet-Debrus C, Calberg-Bacq C-M. Potential of varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells. Gene Ther 1997; 4:560-9.
17. Block A, Chen S-H, Kosai K-I, et al. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 1997; 15:25-34.
18. Mizuno M, Yoshida J, Colosi P, et al. Adeno-associated virus vector containing the herpes simplex virus thimidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res 1998; 89:76-80.
19. Hall SJ, Mutchnik S, Yang G, et al. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther 1999; 6:54-63.
20. Shalev M, Kadmon D, The B, et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 2000; 163:1747-50.
21. Beck C, Cayeux S, Lupton S, et al. The thymidine kinase/ganciclovir-mediated “suicide” effect is variable in different tumor cells. Hum Gene Ther 1995; 6:1525-30.
22. Yiang L, Hwang R, Chiang Y, et al. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. Clin Cancer Res 1998; 4:731-41.
23. Boucher PD, Ruch RJ, Shewach DS. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum Gene Ther 1998; 9:801-14.
24. Rosolen A, Frascella E, di Francesco C, et al. In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Ther 1998; 5:113-20.
25. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000; 60:249-71.
26. Russel WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81:2573-604.
27. Elshami AA, Saavedra A, Zhang H, et al. Gap junction play a role in the `bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3:85-92.
28. Kumar NM, Gilula NB. The gap junction communication channel. Cell 1996; 84:381-8.
29. Ishii-Morita H. Mechanism of `bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 1997; 4:244-51.
30. Commentary. Bystander effects in enzyme/prodrug gene therapy. Hum Gene Ther 1997;8:1733-6.
31. Yiang L, Chiang Y, Lenz H-J, et al. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther 1998; 9:719-28.
32. Mesnil M, Yamasaki H. Bystander effects in herpes simplex virus-thimidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000; 60:3989-99.
33. Qiao J, Black ME, Caruso M. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther 2000; 11:1569-76.
34. Carriò M, Mazo A, Lòpez-Iglesias C, et al. Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells. Results in variable efficiency on the bystander killing: implications for gene therapy. Int J Cancer 2001; 94:81-8.
35. Latham JPF, Searle PF, Mautner V, et al. Prostate-specific antigen promoter/enhanced driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60:334-41.
36. Moore PS, Sipos B, Orlandini S, et al. Genetic profile of 22 pancreatic carcinoma cell lines: analysis of K -ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001; 439:798-802.
37. Pizzato M, Franchin E, Calvi P, et al. Production and characterization of a bicistronic moloney-based retroviral expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. Gene Ther 1998; 5:1003-7.
38. Sohn TA, Yeo CJ. The molecular genetics of pancreatic ductal carcinoma: a review. Surg Oncol 2000; 9:95-101.
39. Schwarz RE, McCarty TM, Peralta EA, et al. An orthotopic in vivo model of human pancreatic cancer. Surgery 1999; 126:562-7.
40. DiMaio JM, Clary BM, Via DF, et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116:205-13.
41. Carriò M, Romagosa A, Mercade E, et al. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther 1999; 6:547-53.